Previous 10 | Next 10 |
- AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST LONDON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopha...
Volatility watch: Cinemark (NYSE: CNK ) and On Semiconductor (NASDAQ: ON ) have both seen sizable jumps in short interest positions, while the daily swings in Stitch Fix (NASDAQ: SFIX ) could to get large amid a high level of short interest even as Wall Street firms turn bullish. Op...
The following slide deck was published by Autolus Therapeutics plc in conjunction with this Read more ...
LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO3 data presented a...
Autolus Therapeutics PLC (AUTL) Q2 2020 Earnings Conference Call August 06, 2020, 08:30 ET Company Participants Lucinda Crabtree - VP, IR & Corporate Communications Christian Itin - Chairman & CEO Andrew Oakley - CFO & SVP Conference Call Participants Mara Golds...
The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2020 Q2 earnings Read more ...
Autolus Therapeutics (NASDAQ: AUTL ) : Q2 GAAP EPS of -$0.62 beats by $0.10 . Revenue of $0.29M (-14.7% Y/Y) misses by $0.04M . Press Release More news on: Autolus Therapeutics plc, Earnings news and commentary, Healthcare stocks news,
LONDON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial and operational results for the second quarter ended June 30, 2020. ...
LONDON, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Dr. Jay T Backstrom to its Board of Directors, effective August 1, 20...
LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2020 financial results and operational highlight...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...